ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout

FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare

Michele B. Kaufman, PharmD, BCGP  |  March 12, 2019

The FDA has issued a boxed warning for febuxostat after a safety study found an increased risk of heart-related and other death in RA patients…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:cardiovascularColchicineDrug SafetyFebuxostatFood and Drug AdministrationGoutSafetyU.S. Food and Drug Administration (FDA)

Coding Corner Question: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

A 60-year-old man returns for a follow-up related to his diagnoses of rheumatoid arthritis and chronic gout of his right ankle and foot, without tophi. He reports the gout flares have subsided in his ankle. He takes 450 mg of allopurinol daily. He has rheumatoid factor-positive rheumatoid arthritis, which previously affected multiple sites, without organ…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisRheumatoid Arthritis Tagged with:Current Procedural Terminology (CPT) codesGout

Coding Corner Answer: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 CPT: 99213 ICD-10: M1a.0710, M05.79 History—The history of present illness was extended. The review of systems was extended, and two past family social history elements were documented. This makes the history level detailed. Examination—Five systems were examined. This makes the exam level detailed. Medical decision…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisRheumatoid Arthritis Tagged with:Current Procedural Terminology (CPT) codesGout

Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels

Lara C. Pullen, PhD  |  November 26, 2018

An exploratory analysis of a canakinumab clinical trial has shown the interleukin 1β inhibitor may significantly reduce patients’ risk for gout flares. During the study, patients using canakinumab experienced this decreased risk, but the treatment did not change serum uric acid levels…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:anti-interleukincanakinumabflareGout

Older Gout Patients More Likely to Develop Hearing Impairment

Lara C. Pullen, PhD  |  October 15, 2018

Previous research has established that gout and hearing loss have shared risk factors. Now, a recent study found gout itself is associated with an increased risk of hearing loss in adults 65 years and older…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Gouthearing lossolderpatient care

Allopurinol for Gout an Unlikely Contributor to Kidney Disease

Reuters Staff  |  October 8, 2018

NEW YORK (Reuters Health)—Allopurinol does not appear to contribute to decline in kidney function and may actually protect renal function in patients with gout, according to a large population-based study. Gout affects around 4% of Americans and often occurs alongside chronic kidney disease (CKD), Dr. Tuhina Neogi from Boston University School of Medicine and colleagues…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Allopurinolchronic kidney diseaseGoutkidney

5 Takeaways from the ACR’s Gout Clinical Quality Measures

Carina Stanton  |  August 7, 2018

With electronic clinical quality measures tailored for treating gout patients, physicians and their teams now have tools to measure and improve gout care performance and outcomes…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Goutpatient careQuality Measuresurate-lowering therapies

Gout Emergency Department Visits Up

Lara C. Pullen, PhD  |  July 16, 2018

In the past nine years, visits to the emergency department by gout patients have increased by almost 27%. Researchers suggest physicians may not adequately be addressing the burden of gout and the underlying accumulation of uric acid, driving the dramatic increase in emergency department visits in the U.S…

Filed under:ConditionsGout and Crystalline Arthritis

New Study Raises Cardiovascular Questions about Febuxostat for Gout

Lara C. Pullen, PhD  |  April 30, 2018

New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinolcardiovascularFebuxostathyperuricemiarisk

Pathophysiology of Gouty Tophi

Lara C. Pullen, PhD  |  March 19, 2018

In a recent study, researchers examined synovial fluid and non-inflamed tophi from the acutely inflamed joints of patients with gout, finding that monosodium urate (MSU) crystals trigger a distinct physiological NETosis pathway that coats MSU crystals in DNA that persists in tissues as gouty tophi…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Goutmonosodium urate crystalsNETosisneutrophils

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 60
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences